Discover Amgen Inc.'s latest 8-K filing detailing its 2.000% Senior Notes due 2026 and stock updates. Stay informed on significant corporate developments and compliance.
Discover Amgen's impressive Q2 2025 results with $9.179B revenue and $1.432B net income. Learn why it's a buy for investors!
Explore Amgen Inc.'s latest 8-K filing detailing common stock and senior notes. Key insights on financing and corporate strategy included.
Explore Amgen Inc.'s latest 8-K report detailing common stock, senior notes, and financial strategies as of May 1, 2025. Key insights on debt management and market positioning.
Explore the current challenges in the biotech sector and discover resilient companies like Amgen, Gilead, Moderna, Illumina, and Vertex that present promising investment opportunities.